| Basics |
Agenus Inc.
Agenus Inc along with its subsidiaries is a pharmaceutical company. It is engaged in discovery and development of revolutionary new treatments that engage the body's immune system to benefit patients suffering from cancer.
|
| IPO Date: |
February 4, 2000 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$170.53M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.12 | 3.44%
|
| Avg Daily Range (30 D): |
$0.32 | 5.81%
|
| Avg Daily Range (90 D): |
$0.22 | 6.02%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.41M |
| Avg Daily Volume (30 D): |
1.1M |
| Avg Daily Volume (90 D): |
.95M |
| Trade Size |
| Avg Trade Size (Sh.): |
277 |
| Avg Trade Size (Sh.) (30 D): |
140 |
| Avg Trade Size (Sh.) (90 D): |
137 |
| Institutional Trades |
| Total Inst.Trades: |
1,272 |
| Avg Inst. Trade: |
$1.67M |
| Avg Inst. Trade (30 D): |
$1.93M |
| Avg Inst. Trade (90 D): |
$1.75M |
| Avg Inst. Trade Volume: |
.04M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.76M |
| Avg Closing Trade (30 D): |
$3.23M |
| Avg Closing Trade (90 D): |
$2.71M |
| Avg Closing Volume: |
38.85K |
|
|
| Financials |
| |
TTM |
Q4 2024 |
FY 2024 |
|
Basic EPS
|
$-10.59
|
$-1.94
|
$-10.59
|
|
Diluted EPS
|
$-10.59
|
$-1.94
|
$-10.59
|
|
Revenue
|
$ 103.46M
|
$ 26.84M
|
$ 103.46M
|
|
Gross Profit
|
$ 102.98M
|
$ 26.72M
|
$ 102.98M
|
|
Net Income / Loss
|
$ -232.27M
|
$ -46.81M
|
$ -232.27M
|
|
Operating Income / Loss
|
$ -120.48M
|
$ -25.9M
|
$ -120.48M
|
|
Cost of Revenue
|
$ .49M
|
$ .12M
|
$ .49M
|
|
Net Cash Flow
|
$ -35.45M
|
$ -4.3M
|
$ -35.45M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Apr 12, 2024:
1:20
|
|
Oct 03, 2011:
1:6
|
|
|
|
